Company news

Schering-Plough ended its partnership with Novacea after its prostate cancer compound Asentar failed in clinical trials. The companies ended a late-stage study of the drug late last year citing an "imbalance" of deaths. Patients taking Asentar died more often than those taking a standard treatment. Asentar rights will be returned to Novacea. Despite the higher-than-expected number of deaths, the company said in published reports it still believes Asentar is a safe drug and called Schering-Plough's decision unexpected.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.